OTCMKTS:PDDPF Medexus Pharmaceuticals (PDDPF) Stock Price, News & Analysis $2.14 0.00 (0.00%) As of 08/4/2023 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Medexus Pharmaceuticals Stock (OTCMKTS:PDDPF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PDDPF alerts:Sign Up Key Stats Today's Range$2.11▼$2.4250-Day Range$2.14▼$2.1452-Week Range$1.70▼$3.99Volume39,966 shsAverage Volume4,355 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company. It provide healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company products include Rasuvo, Metoject and Rupall. Medexus was founded by Sylvain Chretien in January 2008 and is headquartered in Verdun, Canada. Read More Receive PDDPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PDDPF Stock News HeadlinesPositive Growth Outlook for Medexus Pharmaceuticals Inc. Amid Strategic Expansion and Stable PerformanceFebruary 9, 2025 | tipranks.comStifel cuts Medexus Pharma stock rating to Hold, target to C$3.45February 7, 2025 | msn.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.July 11 at 2:00 AM | Porter & Company (Ad)Medexus targets $100M annual revenue for GRAFAPEX within 5 years post-launchFebruary 6, 2025 | msn.comEarnings call transcript: Medexus Q3 FY2025 shows revenue growth, FDA approvalFebruary 6, 2025 | msn.comMedexus Pharmaceuticals Inc (MDP) Receives a Buy from Raymond JamesFebruary 3, 2025 | markets.businessinsider.comVentum Financial Reaffirms Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)January 30, 2025 | markets.businessinsider.comMedexus Pharmaceuticals Launches Public Offering to Enhance Financial FlexibilityJanuary 27, 2025 | tipranks.comSee More Headlines PDDPF Stock Analysis - Frequently Asked Questions How have PDDPF shares performed this year? Medexus Pharmaceuticals' stock was trading at $2.14 at the beginning of 2025. Since then, PDDPF shares have increased by 0.0% and is now trading at $2.14. How do I buy shares of Medexus Pharmaceuticals? Shares of PDDPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:PDDPF CIKN/A Webwww.medexus.com Phone(514) 762-2626FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (OTCMKTS:PDDPF) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
